MoneyWorks4Me

Onesource Specialty’s partner gets Health Canada nod for Generic Semaglutide Injection

29 Apr 2026 Evaluate

Onesource Specialty Pharma’s partner Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic. The company serves as the CDMO partner on this program, providing scale-up and manufacturing support. The partnership is designed to ensure reliable and scalable commercial supply from the company’s US-FDA approved flagship manufacturing facility in Bengaluru.

OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.

Onesource Specialty Share Price

1534.35 -17.60 (-1.13%)
18-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1876.40
Dr. Reddys Labs. 1180.50
Cipla 1431.85
Lupin 2225.00
Zydus Lifesciences 1117.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: